Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.
Reversible protein-tyrosine phosphorylation is catalyzed by the antagonistic actions of protein-tyrosine kinases (PTKs) and phosphatases (PTPs), and represents a major form of cell regulation. Acute myeloid leukemia (AML) is an aggressive hematological malignancy that results from the acquisition of multiple genetic alterations, which in some instances are associated with deregulated protein-phosphotyrosine (pY) mediated signaling networks. However, although individual PTKs and PTPs have been linked to AML and other malignancies, analysis of protein-pY networks as a function of activated PTKs and PTPs has not been done. In this study, MS was used to characterize AML proteomes, and phospho-proteome-subsets including pY proteins, PTKs, and PTPs. AML proteomes resolved into two groups related to high or low degrees of maturation according to French-American-British classification, and reflecting differential expression of cell surface antigens. AML pY proteomes reflect canonical, spatially organized signaling networks, unrelated to maturation, with heterogeneous expression of activated receptor and nonreceptor PTKs. We present the first integrated analysis of the pY-proteome, activated PTKs, and PTPs. Every PTP and most PTKs have both positive and negative associations with the pY-proteome. pY proteins resolve into groups with shared PTK and PTP correlations. These findings highlight the importance of pY turnover and the PTP phosphatome in shaping the pY-proteome in AML.
Program in Cell Biology, Hospital for Sick Children, Toronto, Canada.|Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.
Jiefei
J
Tong
The Donnelly Centre, University of Toronto, Toronto, Canada.
Mohamed
M
Helmy
Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.|Program in Developmental & Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Canada.
Florence M G
FM
Cavalli
Program in Cell Biology, Hospital for Sick Children, Toronto, Canada.|Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.
Lily
L
Jin
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Jonathan
J
St-Germain
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Robert
R
Karisch
Program in Cell Biology, Hospital for Sick Children, Toronto, Canada.|Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.
Paul
P
Taylor
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Mark D
MD
Minden
Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.|Program in Developmental & Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Canada.|Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Michael D
MD
Taylor
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.|Departmet of Medicine, NYU School of Medicine, New York, NY, USA.
Benjamin G
BG
Neel
The Donnelly Centre, University of Toronto, Toronto, Canada.|Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Gary D
GD
Bader
Program in Cell Biology, Hospital for Sick Children, Toronto, Canada.|Peter Gilgan Centre for Research and Learning, Hospital For Sick Children, Toronto, Canada.|Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Michael F
MF
Moran
D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000378:metabolism*; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism*; D011494:Protein Kinases / Q000378:metabolism*; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D015398:Signal Transduction
D020543:Proteome; D019000:Phosphotyrosine; D011494:Protein Kinases
AML; Kinome; PTPome; Proteome; pYome